Jci_page_head_homepage_01 Jci_page_head_homepage_02
Rajesh K. Thimmulappa, Hannah Lee, Tirumalai Rangasamy, Sekhar P. Reddy, Masayuki Yamamoto, Thomas W. Kensler, Shyam Biswal
Published in Volume 116, Issue 4
J Clin Invest. 2006; 116(4):984–995 doi:10.1172/JCI25790
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Nonlethal dose of LPS induced greater lung inflammation in Nrf2-deficient lungs.

(A and B) BAL fluid analysis of Nrf2–/– and Nrf2+/+ mice after 6 and 24 hours of i.p. injection of LPS (60 μg per mouse). (C) BAL fluid analysis of Nrf2–/– and Nrf2+/+ mice after 6 hours and 24 hours of LPS instillation (10 μg per mouse). (D) Histopathological analysis of lungs by H&E staining 24 hours after instillation of LPS. Arrows indicate accumulation of inflammatory cells in the alveolar spaces. Magnification, ×20. (E) Immunohistology of lungs of both genotypes using anti-mouse neutrophil antibody 24 hours after LPS instillation. Sections were counterstained with hematoxylin. Arrows indicate neutrophils. Magnification, ×40. (F) Myeloperoxidase (MPO) activity in lung homogenates of both genotypes 6 and 24 hours after LPS instillation. (G) Pulmonary edema was assessed by the ratio of wet to dry lung weight 24 hours after LPS instillation. Data are presented as mean α SEM; n = 5. *Differs from vehicle control of the same genotype. Differs from LPS-treated wild-type mic P < 0.05.